Fluorescence-guided resections of malignant gliomas — an overview

Walter Stummer(University of Münster), J.-C. Tonn(LMU Klinikum), H. J. Reulen(Goethe University Frankfurt), Alexander Novotny(Klinikum rechts der Isar), H. Steppe(Ludwig-Maximilians-Universität München)

Unknown

January 1, 2003

10.1007/978-3-7091-6090-9_3

Cited by 125

Related Papers

Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial

|The Lancet Oncology|2006|3.4k

EXTENT OF RESECTION AND SURVIVAL IN GLIOBLASTOMA MULTIFORME

|Neurosurgery|2008|1k

Fluorescence-guided resection of glioblastoma multiforme utilizing 5-ALA-induced porphyrins: a prospective study in 52 consecutive patients

|Journal of neurosurgery|2000|880

Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA–09): a randomised, open-label, phase 3 trial

|The Lancet|2019|581

What is the Surgical Benefit of Utilizing 5-Aminolevulinic Acid for Fluorescence-Guided Surgery of Malignant Gliomas?

|Neurosurgery|2015|368